A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Investigational new drugs

• Publication date

  2017-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10637-016-0399-7PMID 27853996
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets

  2016cited by this paper
• The anti-HER 3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells

  2015cited by this paper
• Genomic spectra of biliary tract cancer

  2015cited by this paper
• Targeting of erbB3 receptor to overcome resistance in cancer treatment

  2014cited by this paper
• Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.

  2014cited by this paper
• Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non‐small cell lung cancer

  2014cited by this paper
• Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms

  2014cited by this paper
• Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy

  2014cited by this paper
• The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells

  2014cited by this paper
• Characterization of EGFR family gene aberrations in cholangiocarcinoma.

  2014cited by this paper
• Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

  2014cited by this paper
• New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.

  2014cited by this paper
• Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

  2014cited by this paper
• Abstract 5606: Detection of circulating tumor DNA in early and late stage human malignancies

  2014cited by this paper
• Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer

  2014cited by this paper
• The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells

  2013cited by this paper
• Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.

  2013cited by this paper
• Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology.

  2013cited by this paper
• The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells

  2013cited by this paper
• Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.

  2013cited by this paper
• Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.

  2012cited by this paper
• Abstract LB-410: Phase I dose escalation study of MM-121, a fully human monoclonal antibody to ErbB3, in patients with advanced solid tumors

  2011cited by this paper
• Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

  2011cited by this paper
• A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

  2011cited by this paper
• HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation.

  2010cited by this paper
• Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

  2010cited by this paper
• Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.

  2010cited by this paper
• An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.

  2010influential reference
• Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

  2009cited by this paper
• Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

  2008cited by this paper
• Platinum-based chemotherapy plus cetuximab in head and neck cancer.

  2008cited by this paper
• Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

  2007cited by this paper
• Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3

  2007cited by this paper
• Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

  2006cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.

  2002cited by this paper

• Advancements in Targeted Therapies for Colorectal Cancer: Overcoming Challenges and Exploring Future Directions

  2025cites this paper
• Emerging importance of HER3 in tumorigenesis and cancer therapy

  2025cites this paper
• DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer

  2024cites this paper
• The Evolving Paradigm of Antibody–Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases

  2024cites this paper
• Transcriptional landscape of DTP-DTEP transition reveals DUSP6 as a driver of HER2 inhibitor tolerance via Neuregulin/HER3 axis

  2023influential citation
• HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target

  2023cites this paper
• HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer

  2023cites this paper
• Mathematical modeling of regulatory networks of intracellular processes – Aims and selected methods

  2023cites this paper
• The HER family as therapeutic targets in colorectal cancer.

  2022cites this paper
• Liver Endothelium Promotes HER3-mediated Cell Survival in Colorectal Cancer with Wild-type and Mutant KRAS.

  2022cites this paper
• HER3 in cancer: from the bench to the bedside

  2022cites this paper
• HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer

  2021cites this paper
• Liver Endothelium Promotes HER3-mediated Cell Survival in KRAS Wild-type and Mutant Colorectal Cancer Cells

  2021cites this paper
• Thirty Years of HER3: From Basic Biology to Therapeutic Interventions

  2021cites this paper
• Liver Endothelium Microenvironment Promotes HER3-mediated Cell Survival in KRAS Wild-type and Mutant Colorectal Cancer

  2021cites this paper
• Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3

  2020cites this paper
• A Critical Review of Second-generation anti-EGFR Monoclonal Antibodies in Metastatic Colorectal Cancer.

  2020cites this paper
• U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer

  2019cites this paper
• HER3-Targeted Affibodies with Optimized Formats Reduce Ovarian Cancer Progression in a Mouse Xenograft Model

  2019cites this paper
• Endothelial Cells Promote Colorectal Cancer Cell Survival by Activating the HER3-AKT Pathway in a Paracrine Fashion

  2018cites this paper
• Clinical development of HER3-targeting monoclonal antibodies: Perils and progress.

  2018cites this paper
• Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

  2017cites this paper
• World Journal of Gastroenterology

  year unknowncites this paper